ArticleThe oncologist2026
Patient-specific 3D-printed HDR surface brachytherapy for basal cell carcinoma in older patients: prospective feasibility and imaging response.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBasal cell carcinoma (BCC) is common in older adults, many of whom are poor surgical candidates, especially for curved and cosmetically sensitive facial sites. High-dose-rate (HDR) surface brachytherapy is effective, but standard flat applicators may fit poorly and increase dose heterogeneity. Patient-specific 3D-printed applicators could improve conformity, yet geriatric BCC data are limited.
objectiveTo assess the feasibility and 12-month outcomes of personalized 3D-printed HDR surface brachytherapy in geriatric patients with BCC.
methodsIn this prospective single-arm study, 15 patients aged ≥65 years with histologically confirmed BCC (predominantly facial) who were unsuitable for surgery received HDR surface brachytherapy using custom 3D-printed applicators. Treatment delivered 51 Gy in 17 fractions with CT-based planning. Repeat CT imaging evaluated applicator fit/reproducibility and target coverage. Acute skin toxicity was graded by RTOG. At 12 months, response was assessed clinically and dermoscopically; cosmesis and quality of life (Dermatology Life Quality Index [DLQI]) were recorded.
resultsAll patients completed treatment. Positioning was highly reproducible (mean setup error <1 mm) with >90% target dose coverage. At 12 months, all lesions achieved complete remission, with no local recurrence on dermoscopy. Acute reactions were mostly mild (73% grade 1), with 13% grade 2 and 13% grade 3; no grade 4 toxicity or serious adverse events occurred. Cosmesis was favorable, and DLQI improved (mean, 10.5 pre-treatment vs 2.9 at 1 year; P < .01).
conclusionsPersonalized 3D-printed HDR surface brachytherapy appears feasible and well tolerated in this small, single-center cohort of older patients with BCC, with favorable 1-year local control and quality-of-life improvement when surgery is contraindicated. However, the limited sample size and single-center design represent limitation, and the observed benefit should be regarded as suggestive rather than definitive.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.